Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 3 1Phase 1 1

Status

Recruiting 58Active not recruiting 56Completed 18Not yet recruiting 16Terminated 7Withdrawn 2Suspended 2

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 7

Sponsor

Cancer Type

Plasma cell 6Other hematologic neoplasm 2Lymphoid 2

Conditions

Multiple Myeloma 6Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

pembrolizumab 116Carboplatin 48Nivolumab 46Paclitaxel 35Cyclophosphamide 35Cisplatin 34Gemcitabine 30atezolizumab 25Specimen Handling 25venetoclax 24Pemetrexed 24Magnetic Resonance Spectroscopy 24fludarabine 22Ipilimumab 22Docetaxel 22Bevacizumab 22Biopsy 21Radiotherapy 20Azacitidine 20Fluorouracil 19Dexamethasone 19Radiosurgery 18durvalumab 17Leucovorin 16olaparib 14Trastuzumab 14Cetuximab 14Capecitabine 14fludarabine phosphate 13Lenalidomide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Terminated × daratumumab × 1 year × Clear all
NCT04824794 2026-05-19

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Genmab

Phase 1/2 Terminated
130 enrolled 40 charts
LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT03757221 2026-05-13

IDARA

University Hospital, Caen

Phase 2 Terminated
55 enrolled
Plasma cell

Multiple Myeloma

NCT03622775 2026-04-24

Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 2 Terminated
13 enrolled 9 charts
Plasma cell

Multiple Myeloma

NCT05590377 2026-01-30

iinnovate-3

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1/2 Terminated
15 enrolled 12 charts
Plasma cell

Multiple Myeloma

NCT05556616 2026-01-29

iinnovate-2

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Terminated
15 enrolled 15 charts
Plasma cell

Multiple Myeloma

NCT05675319 2026-01-05

AlloRelapseMM

Universitätsklinikum Hamburg-Eppendorf

Phase 3 Terminated
28 enrolled
Plasma cell

Multiple Myeloma

NCT04230304 2025-12-30

Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

Mayo Clinic

Phase 2 Terminated
8 enrolled 10 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡